WAM
HRMY icon

Wakefield Asset Management’s Harmony Biosciences HRMY Stock Holding History

Wakefield Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,819
Closed -$451K – 169
2023
Q1 		$451K Buy
13,819
+63
+0.5% +$2.87K 0.19% 129
2022
Q4 		$758K Buy
+13,756
New +$756K 0.32% 100

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wakefield Asset Management's HRMY Position: Q2 2023 in Review

Wakefield Asset Management sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 13,819 shares — an estimated $451K sold.

Wakefield Asset Management first reported a position in HRMY in Q4 2022 and held it in 2 quarters. The position peaked at $758K in Q4 2022. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Wakefield Asset Management reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Wakefield Asset Management sold 13,819 Harmony Biosciences shares in Q2 2023, an estimated $451K.
  • Wakefield Asset Management first reported a position in Harmony Biosciences in Q4 2022 and held it in 2 quarters.
  • Wakefield Asset Management's Harmony Biosciences position peaked at $758K in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Wakefield Asset Management's 13F filing for Q2 2023, filed 1 Aug 2023.